Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilunocitinib
- Development stage
- Unknown
- Lead developer
- Elanco
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ilunocitinib is a veterinary pharmaceutical agent classified as a non-selective Janus kinase (JAK) inhibitor. It is used for the control of pruritus associated with allergic dermatitis and for the management of atopic dermatitis in dogs aged at least 12 months. Ilunocitinib acts by inhibiting JAK1, JAK2, and tyrosine kinase 2 (TYK2), thereby blocking signaling pathways of multiple pruritogenic, pro-inflammatory, and allergy-related cytokines that depend on these enzymes. This mechanism interrupts the itch-scratch cycle characteristic of allergic skin diseases in dogs. Ilunocitinib is not a corticosteroid or antihistamine and has demonstrated efficacy superior to oclacitinib in clinical trials for canine atopic dermatitis[1][2][3][4][5][6][7][8]. The drug is administered orally once daily.
- Brand names
- Zenrelia
- Other names
- ilunocitinibZenreliaLY-3411067LY3411067LY 3411067
02
Targets
Beyond the preview
Go deeper on ilunocitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilunocitinib.